文献速递中毒与环境急症

迷幻药呼叫:澳大利亚毒物信息中心与经典迷幻药相关呼叫分析

The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
PubMed 文献 · Clin Toxicol (Phila) · 2024-05-16
一句话结论2014至2022年新南威尔士州毒物信息中心经典迷幻药相关呼叫从45例增至105例,85%来自或转诊医院,单药暴露幻觉27.6%、心动过速18.1%、癫痫2.9%。

该研究回顾性分析2014年1月至2022年12月新南威尔士州毒物信息中心737例经典迷幻药暴露呼叫,其中LSD 352例(47.8%)、赛洛西宾347例(47.0%)。呼叫从2014年45例增至2022年105例,625例(85%)来自或转诊医院,249例(33.8%)存在共摄入。单药暴露最常见临床特征为幻觉(27.6%)、胃肠道症状(21.7%)和心动过速(18.1%),癫痫占2.9%。作者认为社区使用增加可能反映迷幻药辅助心理治疗试验带来的公众认知提升,并建议进行安全使用教育。

要点

  • 2014至2022年新南威尔士州毒物信息中心共737例经典迷幻药暴露呼叫,LSD 352例(47.8%)、赛洛西宾347例(47.0%)。
  • 呼叫量从2014年45例增至2022年105例,增长超过一倍;625例(85%)来自或转诊医院。
  • 249例(33.8%)存在与其他物质共摄入;单药暴露最常见为幻觉(27.6%)、胃肠道症状(21.7%)、心动过速(18.1%)。
  • 单药暴露中癫痫发生率为2.9%,作者认为相对高的中毒严重度与临床试验中的安全性形成对比。
  • 作者认为社区使用不受控可能解释较高毒性,临床试验环境可减轻该风险;建议进行安全使用教育。

适用人群与场景

  • 2014年1月至2022年12月向新南威尔士州毒物信息中心报告的经典迷幻药暴露呼叫,包括LSD、赛洛西宾、N,N-二甲基色胺、死藤水、麦司卡林和伊博格碱。
  • 病例以男性为主(77.2%),年龄20至74岁者占65.6%。

红旗征与不能漏的情况

  • 单药暴露中癫痫发生率为2.9%。

研究设计与关键结果

  • 回顾性观察研究,分析2014年1月至2022年12月新南威尔士州毒物信息中心737例经典迷幻药暴露呼叫。
  • 暴露物质:LSD 352例(47.8%)、赛洛西宾347例(47.0%)、N,N-二甲基色胺28例(3.8%)、死藤水4例(0.5%)、麦司卡林4例(0.5%)、伊博格碱2例(0.3%)。
  • 呼叫量从2014年45例增至2022年105例,增长超过一倍;625例(85%)来自或转诊医院。
  • 249例(33.8%)存在与其他物质共摄入。
  • 单药暴露最常见临床特征:幻觉27.6%、胃肠道症状21.7%、心动过速18.1%;癫痫2.9%。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,迷幻药暴露呼叫增加及其中报告显著毒性,可能反映社区使用增加;这可能部分由迷幻药辅助心理治疗试验关注度上升及公众认知提高驱动。
  • 作者认为,社区使用不受控可能解释相对较高的中毒严重度,而临床试验环境可减轻该风险。
  • 作者认为,关于安全使用的教育可能有用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Australia. We aim to describe calls to New South Wales Poisons Information Centre relating to exposures to classical psychedelics including lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, ayahuasca, mescaline and ibogaine.

METHODS: This is a retrospective observational study of calls to New South Wales Poisons Information Centre between January 2014 and December 2022. We identified exposures to classical psychedelics within New South Wales Poisons Information Centre database and measured the annual number of exposures, source of call (hospital, health care worker, member of the public), co-ingested substances, clinical features and advice given.

RESULTS: There were 737 calls related to relevant psychedelic exposures; 352 (47.8 per cent) to lysergic acid diethylamide, 347 (47.0 per cent) to psilocybin, 28 (3.8 per cent) to N,N-dimethyltryptamine, 4 (0.5 per cent) to ayahuasca, 4 (0.5 per cent) to mescaline and 2 (0.3 per cent) to ibogaine. Cases were predominantly male (77.2 per cent) and aged between 20 and 74 years (65.6 per cent). Psychedelic calls more than doubled from 45 in 2014 to 105 in 2022 and 625 (85 per cent) of all calls were either from or referred to hospital. Co-ingestion of psychedelics with another substance occurred in 249 (33.8 per cent) of calls and the most frequent clinical features related to single substance psychedelic exposures were hallucinations (27.6 per cent), gastrointestinal symptoms (21.7 per cent) and tachycardia (18.1 per cent). Seizures occurred in 2.9 per cent of single substance psychedelic exposures.

DISCUSSION: Increasing incidence of psychedelic exposure calls, including those reporting significant toxicity, likely reflects increasing community use. This may in part be driven by increasing interest in psychedelic assisted psychotherapy trials subsequently increasing public awareness.

CONCLUSION: Relatively high poisoning severity contrasts with safety within clinical trials of psychedelic assisted psychotherapy that may relate to the uncontrolled nature of community use which is mitigated within clinical trial environments. Education about safe use may be useful.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Wilkes R, Roberts DM, Liknaitzky P, et al. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics. Clin Toxicol (Phila). 2024. PMID: 38753585. doi:10.1080/15563650.2024.2346612

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。